|
|
||||||||
From the Department of Neurology (H.H.S., S.H.), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; and Occupational Medicine Services (V.A.C.), Hartford Medical Group, Wethersfield, CT.
Address correspondence and reprint requests to Dr. Herbert H. Schaumburg, Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461; e-mail: schaumbu{at}aecom.yu.edu
Manganese neurotoxicity developed in a highly exposed worker after asymptomatic, moderate hepatic dysfunction from hepatitis C infection. Antiviral therapy was accompanied by resolution of increased blood manganese levels and neurologic improvement. Even asymptomatic hepatic dysfunction may impair manganese clearance and place highly exposed persons at risk for toxicity.
Disclosure: The authors report no conflicts of interest.
Received November 17, 2005. Accepted in final form March 23, 2006.
This article has been cited by other articles:
![]() |
A. Stepens, I. Logina, V. Liguts, P. Aldins, I. Eksteina, A. Platkajis, I. Martinsone, E. Terauds, B. Rozentale, and M. Donaghy A Parkinsonian Syndrome in Methcathinone Users and the Role of Manganese N. Engl. J. Med., March 6, 2008; 358(10): 1009 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. A. de Bie, R. M. Gladstone, A. P. Strafella, J.-H. Ko, and A. E. Lang Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse Arch Neurol, June 1, 2007; 64(6): 886 - 889. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |